Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating AMG 562 in relapsed/refractory DLBCL, MCL, or follicular lymphoma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden [Phase 2]
Phase 2 trial evaluating a chemotherapy-free combination of copanlisib (PI3K inhibitor) with obinutuzumab in previously untreated follicular…
-
CLINICAL_TRIALS trial_result · 2024-03-12Clinical Trial Update: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies [Phase 1]
Phase 1 clinical trial update examining idelalisib after allogeneic HSCT in B-cell malignancies; the study is terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma [Phase 1, Phase 2]
Clinical trial of mocetinostat in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma terminated; results posted.
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-02-08FDA Approved: VIVIMUSTA — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for VIVIMUSTA (bendamustine hydrochloride) filed by Azurity Pharmaceuticals, Inc., to update/exp…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) [Phase 2]
The phase 2 TIDAL trial of Zandelisib (ME-401) in follicular lymphoma, non-Hodgkin lymphoma, and marginal zone lymphoma was terminated, with…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…
-
CLINICAL_TRIALS trial_result · 2024-01-22Clinical Trial Update: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma [Phase 3]
A Phase 3 trial comparing a proposed rituximab biosimilar (DRL_RI) to MabThera in follicular lymphoma has completed with results posted.
-
FDA approval · 2024-01-11FDA Approved: BELRAPZO — Supplemental Application (Eagle Pharmaceuticals, Inc)
The FDA approved a supplemental application for Belrapzo (bendamustine hydrochloride) submitted by Eagle Pharmaceuticals, Inc. The action up…
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Betalutin in relapsed non-Hodgkin lymphoma has completed. The study included follicular lymphoma, with r…
-
CLINICAL_TRIALS trial_result · 2024-01-03Clinical Trial Update: Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213) [Phase 2]
Open-label Phase 2 study of parsaclisib in Japanese participants with relapsed or refractory follicular lymphoma (CITADEL-213); results from…
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating obinutuzumab, polatuzumab vedotin, and lenalidomide in relapsed or refractory follicular lymphoma and rituximab w…
-
CLINICAL_TRIALS trial_result · 2023-12-22Clinical Trial Update: Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL [Phase 1]
Phase 1 clinical trial update on safety and efficacy of betalutin with rituximab in follicular lymphoma, completed with posted results in 20…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) [Phase 3]
A Phase III multicenter randomized trial comparing RIT versus ASCT in relapsed/refractory follicular lymphoma; status and results are not pr…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) [Phase 3]
Phase 3 trial COASTAL evaluating Zandelisib in combination with Rituximab in indolent non-Hodgkin lymphoma was terminated; results were post…
-
CLINICAL_TRIALS trial_result · 2023-12-05Clinical Trial Update: Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma [Phase 2]
Phase 2 trial investigating Revlimid (lenalidomide) at 25 mg with R-CHOP in follicular lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update for CD19-targeted CAR T cells in relapsed/refractory non-Hodgkin lymphoma, including DLBCL and follicular lymphoma, wit…
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating combination of tazemetostat with rituximab in relapsed/refractory follicular lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma [Phase 2]
Phase 2 trial evaluating ublituximab followed by response-driven addition of umbralisib for treatment-naive follicular lymphoma or marginal …
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 trial comparing Loncastuximab Tesirine to Idelalisib in relapsed or refractory follicular lymphoma was terminated with posted result…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating obinutuzumab, rituximab, polatuzumab vedotin, and venetoclax in relapsed/refractory follicular lympho…
-
FDA approval · 2023-10-05FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lena…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-08-14Clinical Trial Update: Dose Optimization Study of Idelalisib in Follicular Lymphoma [Phase 3]
Phase 3 dose optimization study of idelalisib in follicular lymphoma has been terminated with results posted.